Navigation Links
Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
Date:9/2/2010

SAN DIEGO, Sept. 2 /PRNewswire/ -- Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental product candidate, fidaxomicin, will be presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) to be held at the Boston Convention and Exhibition Center in Boston on September 12-15, 2010.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Fidaxomicin abstracts and speakers include:"Randomized Controlled Trial (RCT) of Fidaxomicin (FDX) Versus Vancomycin (VAN) in Treatment of Recurrent Clostridium difficile Infection (CDI)"Oral Presentation: Oliver Cornely, M.D.

Tuesday, September 14, 2010 9:00 am - 9:15 am Eastern Time

Presentation number: L1-1305 in 253A

"Clostridium difficile Strain Type as Determined by Restriction Endonuclease Analysis (REA) Typing in Two Phase III Trials of Fidaxomicin vs Vancoymcin: Treatment Outcome for the Epidemic BI/NAP1/027 Strain"Oral Presentation: Dale N. Gerding, M.D.

Tuesday, September 14, 2010 9:15 am - 9:30 am Eastern Time

Presentation number: L1-1306 in 253A

"Correlation of the ATLAS Bedside Scoring System And Its Components With Cure and Recurrence of Clostridium difficile Infection (CDI)"Poster Presentation: Mark A. Miller, M.D.

Tuesday, September 14, 2010 11:15 am - 1:15 pm Eastern Time

Presentation number: K-1692 in Exhibit Hall B1

"Use of Concomitant Antibiotics (CA) Has a Deleterious Effect on Outcomes Durin
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
2. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
3. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
4. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
5. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
6. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
7. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
8. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
9. Pfizer to Acquire FoldRx Pharmaceuticals
10. Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China
11. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... -- Syneron Medical Ltd. (NASDAQ: ELOS ), a ... new PicoWay® device has received CE Mark indication to ... lesions on any skin type. PicoWay is a new ... wavelengths, which utilizes Syneron,s proprietary PicoWay technology to deliver ... of a second, known as picosecond pulses. Syneron will ...
(Date:7/28/2014)... July 28, 2014  ALPHAEON Corporation ... healthcare and subsidiary of Strathspey Crown ... Recommended Nutriceuticals (PRN) ® , a leading ... products for dry eye and macular ... transaction worth up to $55M. ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical ... CCM ), a leading specialty hospital management ... radiotherapy and diagnostic imaging centers in China ... its Board of Directors declared a special cash dividend ... Depositary Share ("ADS")) on the Company,s outstanding ordinary shares. ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3Concord Medical Declares Special Dividend 2
... , WASHINGTON, Dec. 11 Nabe News ... medicines are in development to fight diabetes. The report details a ... clinical trials and awaiting approval by the U.S. Food and Drug Administration. ... ( PhRMA ). , Diabetics do not produce or properly use ...
... R.I., Dec. 11 CVS Caremark (NYSE: CVS ... Vice President and Chief Human Resources Officer, effective January 1, ... his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) , ... has more than 30 years of human resources experience. ...
Cached Medicine Technology:183 New Medicines in Development for Diabetes 2CVS Caremark Names New Chief Human Resources Officer 2
(Date:7/28/2014)... 28, 2014 A lush green lawn offers ... the summer. However, the summer heat, lack of rain, foot ... brown, weak and unhealthy. The Grounds Guys recommends these suggestions ... a lawn once a week and set the height on ... protects the grass roots from heat and allows roots to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A January ... reduction of gluten intake in those who were self-diagnosed ... Mittry, director of nutrition for San Diego health and ... various gluten considerations for those who are unclear about ... explains that gluten is a protein, found in wheat, ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Quincy Bioscience, ... , is pleased to announce the release of the ... company president and co-founder Mark Underwood. , The Brain ... information, offering useful techniques for readers to improve memory ... an unavoidable conclusion, The Brain Health Guide provides ways ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
(Date:7/28/2014)... -- Elementary school students seem to be satisfied with the ... new study of school officials. , , New meal standards ... into effect in the fall of 2012. At the time, ... throw away most of their food. But the new study ... case. , , "The updated meals standards are resulting in ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Healthy School Lunches Get Thumbs Up From Students 2
... Infuser, a,medical device used extensively in Combat Support Hospitals to treat ... to,save the life of an Omaha, NE Police Officer. , ... during a traffic stop. One of the bullets,hit him in the ... "Injury to this area is ...
... don,t respond at first not helped by maintenance treatment, ... Maintenance therapy using low-dose peginterferon doesn,t help patients with ... initial round of treatment, new research suggests. , The ... with liver disease over the course of four years. ...
... can outperform animal and human derived serum in CHO cell culture. ... ... -- Cellastim has proven to be a robust replacement for serum ... kinetics and productivity of CHO cell lines across a variety of ...
... statement by Betsy Ryan, President and CEO, New Jersey Hospital ... today announced that six New Jersey hospitals will share funding ... news for those facilities, but the more sobering headline is ... away. While a worthy effort, clearly the needs of New ...
... Calif., Dec. 3 ThermoGenesis,Corp. (Nasdaq: KOOL ... process and store adult stem cells, said today that ... Board of Directors to resign as,the Chief Executive Officer ... board has named Matthew T. Plavan, the Company,s Executive,Vice ...
... Dec. 3 The makers of TYLENOL(r) Warming,Liquids have embarked ... so they can warm up. Already a success in New ... complimentary,transportation within the city limits. , ... the city limits of the,District of Columbia, with a maximum ...
Cached Medicine News:Health News:Belmont(R) Rapid Infuser Helps Save Officer's Life 2Health News:Hepatitis C Therapy Useless for Some 2Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 2Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 3Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 4Health News:ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones 5Health News:The Makers of TYLENOL(R) Warming Liquids Offer Free 'Warming' Taxi Rides in Washington, D.C. 2
Stryker Instruments, the leader in surgical helmets, offers its 4th generation of personal protection systems for todays surgical environment the Sterishield T4 System....
... The PROVISION Surgical Helmet System from ... and protection. This system helps meet OSHA ... body fluids, while creating a new standard ... addition to the PROVISION Helmet System from ...
...
... ground has a large surface ... For use with minicrocodile clip ... (1.75 in) long, 3.1 cm ... package contains 50 individually sealed ...
Medicine Products: